Kineret (Anakinra)

Anakinra, the active ingredient in Kineret, is a interleukin‑1 receptor antagonist presented as a subcutaneous injection for use in inflammatory disorders. It blocks interleukin‑1 activity and is prescribed for conditions such as rheumatoid arthritis, CAPS, familial Mediterranean fever and systemic juvenile idiopathic arthritis.

GNH USA supplies Kineret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kineret is an interleukin‑1 receptor antagonist indicated for several inflammatory and autoinflammatory diseases.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression in adult patients. Cryopyrin‑associated periodic syndromes (CAPS): diminishes systemic inflammation and fever episodes. Familial Mediterranean fever: decreases frequency and severity of febrile attacks. Systemic juvenile idiopathic arthritis: controls systemic features and joint involvement in children.

Kineret may cause a range of adverse reactions, most of which are related to injection or immune modulation.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Headache. - Nausea. - Upper respiratory tract infection. - Mild fever. - Arthralgia.

Serious or Rare Side Effects: - Neutropenia or other significant reductions in white blood cells. - Serious infections, including sepsis and opportunistic infections. - Severe hypersensitivity reactions, such as anaphylaxis. - Hepatic enzyme elevations. - Development of anti‑drug antibodies. - Rare cases of malignancy reported in long‑term use.

Before initiating Kineret, clinicians should evaluate patient history and monitor for potential complications.

Monitor blood counts: perform regular complete blood count assessments. Screen for active infections: defer treatment if serious infection is present. Assess renal function: adjust use in patients with severe renal impairment. Avoid live vaccines: vaccination with live attenuated organisms can increase infection risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kineret can interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: increased risk of vaccine‑derived infection. - Concurrent use of other IL‑1 blockers: additive immunosuppression. - Cytotoxic chemotherapy: heightened susceptibility to infections.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may amplify infection risk. - Broad‑spectrum antibiotics: can mask signs of infection. - Non‑live vaccines: monitor immunogenic response and timing.